Torrent Pharma gains on getting nod for Baricitinib for COVID-19 in India
Torrent Pharmaceuticals Limited announced that it has confirmed a royalty-free, non-exclusive voluntary licensing agreement with Eli Lilly & Company for Baricitinib for COVID-19 in India.
Through this agreement, Torrent Pharma has joined the group of leading Indian pharmaceutical companies for Baricitinib for COVID-19 in India. Baricitinib has received a nod by Central Drugs Standard Control Organisation (CDSCO), India for restricted emergency use in combination with Remdesivir for the treatment of suspected or laboratory-confirmed COVID-19 in hospitalised adults, who are in need of supplemental oxygen, invasive mechanical ventilation or extracorporeal membrane oxygenation.
Within the ambit of the agreement, Lilly has given the licence to Torrent for manufacturing & distribution of Baricitinib in India going hand-in-hand with Lilly’s other licenced partners. This agreement will enable Torrent Pharma to reach a greater number of patients in India and also, cater to the efforts in effectively treating patients affected by the pandemic.
Torrent Pharmaceuticals Limited is a pioneer pharma company in initiating the concept of niche marketing in India and is ranked amongst the leaders in the therapeutic segment of cardiovascular (CV), central nervous system (CNS), gastro-intestinal (GI) and women healthcare (WHC). The company also has significant presence in diabetology, pain management, gynaecology, oncology and anti-infective segments.
The share of Torrent Pharma was trading at Rs 2,769.75, which is 1.62 per cent up on BSE